Literature DB >> 30852578

Dopamine Agonists: From the 1970s to Today.

Renata S Auriemma1, Rosa Pirchio1, Dario De Alcubierre1, Rosario Pivonello1, Annamaria Colao2.   

Abstract

The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Bromocriptine; Cabergoline; Dopamine agonists; Hyperprolactinemia; Lisuride; Pergolide; Pituitary tumor; Quinagolide

Mesh:

Substances:

Year:  2019        PMID: 30852578     DOI: 10.1159/000499470

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  Artesunate exerts anti-prolactinoma activity by inhibiting mitochondrial metabolism and inducing apoptosis.

Authors:  Weiyu Zhang; Qiu Du; Piaopiao Bian; Zheng Xiao; Xin Wang; Yajuan Feng; Hou Feng; Ziyan Zhu; Nailin Gao; Diming Zhu; Xiang Fan; Yonghong Zhu
Journal:  Ann Transl Med       Date:  2020-07

Review 2.  Understanding the role of dopamine in cancer: past, present and future.

Authors:  Christopher E Grant; Amy L Flis; Bríd M Ryan
Journal:  Carcinogenesis       Date:  2022-06-27       Impact factor: 4.741

Review 3.  Secretion and Function of Pituitary Prolactin in Evolutionary Perspective.

Authors:  Arpád Dobolyi; Szilvia Oláh; Dávid Keller; Rashmi Kumari; Emese A Fazekas; Vivien Csikós; Éva Renner; Melinda Cservenák
Journal:  Front Neurosci       Date:  2020-06-16       Impact factor: 4.677

Review 4.  Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Authors:  Claudia Pivonello; Roberta Patalano; Mariarosaria Negri; Rosa Pirchio; Annamaria Colao; Rosario Pivonello; Renata Simona Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

Review 5.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

Review 6.  Metabolic effects of prolactin.

Authors:  Rosa Pirchio; Chiara Graziadio; Annamaria Colao; Rosario Pivonello; Renata S Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.